In a crowded field, GSK's CSO explains their choice of the FGF21 molecule "Effie" was driven by three specific technical advantages: a longer half-life enabling monthly dosing for sicker patients, easier manufacturing via mammalian systems, and the lowest immunogenicity profile compared to competitors.
After famously retreating from oncology, GSK's re-entry is not a broad effort. Their CSO clarifies a focused strategy anchored in two key areas: hematology (blood cancers) and solid tumors that are genetically unstable (DMMR/MSI high), with a particular emphasis on women's cancers like endometrial cancer.
GSK's CSO reveals their "bolt-on" deal-making focuses on late-stage clinical assets that may have failed trials or have suboptimal profiles. They acquire these assets when they believe a better trial design or repositioning can unlock the molecule's true potential, as exemplified by their acquisition of Momalotinib.
When asked about complex antibodies like ADCs and bispecifics, GSK's CSO emphasizes that extending a drug's duration is a primary innovation. He highlights a severe asthma treatment dosed just twice a year as a prime example of creating significant patient value before adding further engineering complexity.